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In this issue, Chang et al. (2011) report a small molecule screen against the reconstituted DnaK-DnaJ-GrpE
chaperone cycle. Through this approach, they identified myricetin as an inhibitor of DnaJ-stimulated DnaK
ATPase activity, indicating the potential for their screening approach to identify modulators of emergent
properties of protein complexes.Intracellular protein homeostasis, or ‘‘pro-
teostasis,’’ is maintained by molecular
chaperones that bind to unfolded or mis-Figure 1. Hsp70 Chaperone Activity Is Assisted by Cochaperone
Stimulation of ATP Hydrolysis, by Hsp40, and by Nucleotide
Exchange of the NEF
The timing of the Hsp70 chaperone cycle is dictated by the rate of Hsp40-stim-
ulated ATP hydrolysis, which induces substrate binding, and NEF-stimulated
nucleotide exchange, which triggers substrate release. Myricetin allosterically
blocks the bacterial Hsp40 DnaJ from binding to the Hsp70 DnaK, attenuating
ATPase activity to slow, basal levels, and consequently limiting the high-
affinity binding of DnaK to its peptide substrate. The activity of the bacterial
NEF, GrpE, is unaffected by myricetin, such that substrate release from the
Hsp70 cycle is not impeded.folded proteins, preventing
their aggregation in the
crowded intracellular envi-
ronment (Balch et al., 2008).
Imbalances in the activity of
molecular chaperones are
involved in the pathology of
numerous human diseases
such as diabetes and cancer,
and in neurological disorders
including Parkinson’s disease
and Alzheimer’s disease.
Consequently, chaperones
and chaperone complexes
represent important targets
for the development of
small-molecule therapeutics
that modulate intracellular
proteostasis.
One of the most conserved
families of molecular chaper-
ones is the heat-shock 70 kDa
proteins (Hsp70s). Members
of theHsp70 chaperone family
are found in nearly every
organism and intracellular en-
vironment and are intimately
involved in defining intracel-
lular proteostasis through
their involvement in protein
synthesis, folding, degra-
dation, and trafficking (Brod-
sky and Chiosis, 2006).
Hsp70 proteins are character-
ized by a highly conserved
two-domain structure com-
prised of a substrate-binding
domain (SBD) and a nucleo-
tide-binding domain (NBD).144 Chemistry & Biology 18, February 25, 201ATP binding to the NBD induces an open
conformation of the SBD, which has low
affinity for its misfolded or unfolded protein1 ª2011 Elsevier Ltd All rights reservedsubstrates. Substrate affinity is increased
by hydrolysis of ATP toADP,which alloste-
rically alters the SBD structure, leading toa high-affinity closed confor-
mation. Cycling between the
ATP- and ADP-bound states
regulates substrate interac-
tions and thus defines the
activity of the Hsp70 molecule
(Figure 1).
The basic nucleotide-
dependent activity of Hsp70s
is diversified through interac-
tions with cochaperones
such as J-domain containing
proteins (including Hsp40s)
and nucleotide exchange
factors (NEFs) (Szabo et al.,
1994; Kampinga and Craig,
2010). J-proteins facilitate
Hsp70 activity by both recruit-
ing substrates and stimulating
Hsp70 ATPase activity, effec-
tively locking substrates into
the SBD. In contrast, NEFs
facilitate the ADP-ATP
exchange of Hsp70, resetting
Hsp70 in the low-affinity
closed conformation and
promoting substrate release.
Hsp70 cochaperones can
also define intracellular locali-
zation of Hsp70 and substrate
specificity, thus increasing
the diversity of Hsp70 func-
tions in vivo. The importance
of Hsp70 cochaperones in
defining Hsp70 activity is
emphasized by the nearly 4:1
ratio of J-proteins to Hsp70s
in mammalian cells (Kam-
pinga and Craig, 2010).
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functions makes this protein family, in
isolation, a poor target for therapeutics.
The central importance of J-proteins in
defining Hsp70 activity offers both the
promise of and a significant challenge to
developing small molecule strategies to
alter Hsp70 function in vivo: identifying
molecules that specifically inhibit the
Hsp70-J-protein complex. In this issue
of Chemistry and Biology, Chang et al.
(2011) describe a screening approach to
identify molecules that specifically inhibit
the J-protein-induced stimulation of
Hsp70 ATPase activity. Specifically, the
authors present what they refer to as
‘‘gray box screening,’’ which focuses on
identifying small molecules that target
emergent properties of a fully reconsti-
tuted biological pathway.
The authors screened a reconstituted
bacterial Hsp70 pathway including the
Hsp70, J-protein, and NEF homologs
DnaK, DnaJ, and GrpE, respectively.
Specifically, the authors focused on iden-
tifying small molecules that selectively
inhibited the DnaJ-stimulated ATPase
activity of DnaK. Interestingly, when
screening against plant extracts, they
identified the flavonoid myricetin as
a potent inhibitor of DnaJ-dependent
DnaK ATPase activity. Importantly, myri-
cetin did not inhibit the basal DnaK
ATPase activity nor GrpE-mediated nucle-otide exchange, suggesting that it selec-
tively intervenes in DnaJ-dependent
steps of the DnaK chaperone cycle
(Figure 1). NMR analysis revealed that
myricetin bound at a unique site on the
NBD of DnaK, distinct from both the
nucleotide binding site and the DnaJ
binding site. Through biophysical
approaches, the authors demonstrated
that myricetin binding to the novel site
allosterically inhibited DnaJ binding, and
selectively disrupted DnaJ-dependent
ATPase stimulation. Critically, this is
a ligand binding site that could not have
been discovered through traditional
screening using DnaK alone.
The identification of a small-molecule
based screening approach to identify
specific inhibitors of the Hsp70-J-protein
interactions puts forward the tantalizing
possibility of identifying small molecules
that can target specific Hsp70-J-protein
interactions, allowing selective modula-
tion of Hsp70 activity in vivo. Although
the chemical properties of myricetin
preclude its use in drug development,
the identification of the novel myricetin
binding pocket offers a new target for
small molecule drug design. A vital next
step will be the extension to mammalian
J-domain protein-Hsp70 interactions,
wherein the critical goal will be to achieve
discrimination between J-domain binding
partners by small molecule regulators ofChemistry & Biology 18, February 25, 2011Hsp70. This is the test that will both deter-
mine the therapeutic potential of, as well
as pose the greatest challenge to, this
screening strategy.
Beyond the details of the Hsp70
system, the authors provide a proof-of-
principle, demonstrating the utility of their
gray box screening approach to identify
small molecules targeting specific emer-
gent properties of a protein complex.
While the heterogeneity and sheer size
ofmany biological pathways—particularly
those that lack binding-induced enzy-
matic activity—may preclude the general
application of gray box screening, smaller
and better characterized pathways such
as those between Hsp70 and its cocha-
perones will benefit from this approach.REFERENCES
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Cystic fibrosis transmembrane conductance regulator (CFTR) correctors are small molecules that target the
most common cause of cystic fibrosis: misfolded F508del-CFTR. Using differential scanning fluorimetry,
Sampson et al. (2010) identify a CFTR corrector that interacts directly with the CFTR domain affected by
the F508del mutation.Two decades after the identification of
the defective gene responsible for cystic
fibrosis (CF), symptomatic treatment
remains the bedrock of CF patient care.
However, there is optimism in the CFcommunity that this might change shortly.
By exploiting knowledge and under-
standing of the cystic fibrosis transmem-
brane conductance regulator (CFTR) Cl
channel, its physiological role, anddysfunction in CF, the CF community
now stands at the cusp of developing
therapeutics that target the root cause of
the disease. The latest milestone in this
quest was the successful completion ofª2011 Elsevier Ltd All rights reserved 145
